Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan

number of downloads : ?

Use this link to cite this item : https://ir.lib.shimane-u.ac.jp/53563

language	eng
Author	Inoue Daisuke Third Department of Medicine, Teikyo University Chiba Medical Center, 3426-3, Anesaki, Ichihara-shi, Chiba, 299-0111, Japan Muraoka Ryoichi Data Science Group, Clinical Development Department, Ajinomoto Pharmaceuticals Co., Ltd., Tokyo, Japan Okazaki Ryo Third Department of Medicine, Teikyo University Chiba Medical Center, 3426-3, Anesaki, Ichihara-shi, Chiba, 299-0111, Japan Nishizawa Yoshiki Department of Metabolism, Endocrinology, and Molecular Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan Sugimoto, Toshitsugu
Subject	Bisphosphonate; Risedronate; Metabolic syndrome; Life style-related disease; Bone mineral density; Bone turnover markers
Journal Title	CALCIFIED TISSUE INTERNATIONAL
Volume	98
Issue	2
Start Page	114
End Page	122
ISSN	0171-967X
ISSN（Online）	1432-0827
Published Date	2016-02
DOI	10.1007/s00223-015-0071-9
PubMed ID	26466937
Publisher	SPRINGER
NII Type	Journal Article
OAI-PMH Set	Faculty of Medicine
Remark	This study was supported by the Joint Development Program of Ajinomoto Pharmaceuticals Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Funding for writing/editorial support was provided by Ajinomoto Pharmaceuticals Co., Ltd.